Welcome to our dedicated page for Biolinerx news (Ticker: BLRX), a resource for investors and traders seeking the latest updates and insights on Biolinerx stock.
BioLineRx Ltd. develops oncology and rare-disease therapies, with recurring updates centered on GLIX1, APHEXDA (motixafortide), and motixafortide development in solid tumors.
Company news covers GLIX1 clinical development for glioblastoma and other solid tumors under its Hemispherian collaboration, intellectual-property developments tied to GLIX1, financial results, and corporate updates. APHEXDA is approved in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma and is commercialized by partners, while BioLineRx has retained motixafortide rights for solid-tumor programs including metastatic pancreatic cancer.
BioLineRx Ltd. (NASDAQ: BLRX) announced that approximately 65% of patients have been enrolled in the GENESIS Phase 3 trial for motixafortide (BL-8040) aimed at mobilizing hematopoietic stem cells for multiple myeloma autologous transplantation. An interim efficacy analysis is scheduled for the second half of 2020. Depending on results, recruitment may cease if the primary endpoint is met. The trial has seen a lower-than-anticipated patient dropout rate. Results are expected in early 2021, maintaining blinding post-transplantation.
BioLineRx Ltd. (NASDAQ: BLRX) announced its financial results for Q2 2020, showing a net loss of $6.8 million compared to $5.5 million in Q2 2019. Despite a decrease in research and development expenses by 12.5%, total operating loss stood at $5.6 million. The company raised $13.4 million in gross proceeds from direct offerings, strengthening its balance sheet. Upcoming milestones include three key data readouts in clinical trials for pancreatic cancer and stem cell mobilization expected by year-end.
BioLineRx Ltd. (NASDAQ: BLRX) will announce its unaudited financial results for the quarter ending June 30, 2020, on August 6, 2020, before US markets open. A conference call featuring CEO Philip Serlin will occur the same day at 10:00 a.m. EDT. Investors can dial in or access the call via a webcast on the company's Investor Relations page. The conference call replay will be available for two hours post-live and through August 8, 2020, via designated dial-ins.